Nasdaq smmt.

Summit Therapeutics Inc Ordinary Shares SMMT Morningstar Rating Unlock Stock XNAS Rating as of Dec 1, 2023 Summary Chart News Price vs Fair Value …Summit Therapeutics Inc. (NASDAQ:SMMT) is a biotechnology company that focuses on developing treatments to target infectious diseases. The firm is headquartered in Cambridge, Massachusetts.WebDec 4, 2023 · TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders. Insiders own 8.59% of the company shares, while shares held by institutions stand at 64.76% with a share float percentage of 70.85%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 282 institutions that hold shares in the company. Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 ...During the last session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 1.99 million, with the beta value of the company hitting -1.00. At the end of the trading day, the stock’s price was $2.03, reflecting an intraday gain of 4.10% or $0.08. The 52-week high for the SMMT share is $5 ...

Cambridge, MA, October 2, 2020 – Summit (NASDAQ: SMMT) today announces that it has entered into a binding agreement with the Company’s Chief Executive Officer and Executive Chairman, ...

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

By way of example, Summit Therapeutics (NASDAQ:SMMT) has seen its share price rise 106% over the last year, delighting many shareholders. Having said that, unprofitable companies are risky because ...Summit Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. SMMT updated stock price target summary.Nov 28, 2023 · Stock analysis for Summit Therapeutics Inc (SMMT:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Oxford, UK, and Cambridge, MA, US, 25 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, published preclinical data on SMT-571, a ...During the last session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 1.99 million, with the beta value of the company hitting -1.00. At the end of the trading day, the stock’s price was $2.03, reflecting an intraday gain of 4.10% or $0.08. The 52-week high for the SMMT share is $5 ...

Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders. Insiders own 18.50% of the company shares, while shares held by institutions stand at 9.14% with a share float percentage of 11.21%. Investors are also buoyed by the number of investors in a company, with Avenue Therapeutics Inc having a total of 17 institutions that hold shares …Web

Apr 13, 2023 · Summit Therapeutics (NASDAQ:SMMT) is a project of Bob Duggan of Pharmacyclics fame. This is what keeps our hopes in the future of this company alive, even though the company keeps changing so much ...

SMMT Summit Therapeutics Inc Form PRE 14A - Other preliminary proxy statements. ... (NASDAQ:SMMT) Historical Stock Chart From Oct 2023 to Nov 2023 Summit Therapeutics (NASDAQ:SMMT)há 2 dias ... (NASDAQ:SMMT – Get Free Report)'s stock price dropped 3.9% during trading on Friday . The stock traded as low as $1.94 and last traded at ...Title. Nov 27, Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recently. Nov 8, Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 ...Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it has demonstrated the potential of its DDS-04 series of new class ...Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for …Summit Therapeutics Inc Ordinary Shares SMMT Morningstar Rating Unlock Stock XNAS Rating as of Dec 1, 2023 Summary Chart News Price vs Fair Value …

The public float for SMMT is 111.75M, and currently, short sellers hold a 9.57% ratio of that floaft. The average trading volume of SMMT on November 08, 2023 was 1.02M shares. SMMT) stock’s latest price update. Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has plunge by -12.16relation to previous closing price of 2.18.Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on ...Follow. Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors ...WebFiscal Q3 2023 ended 9/30/23. Reported on 11/7/23. Get the latest Summit Therapeutics Inc (SMMT) real-time quote, historical performance, charts, and other financial information to help you make...Mar 24, 2021 · Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of ... CEO. Website. 2003. 77. Bob Duggan. https://www.summittxinc.com. Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily …2 de nov. de 2023 ... (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice ...

Summit Therapeutics Inc. Common Stock (SMMT) 0 Add to Watchlist Add to Portfolio SMMT SMMT INSIDER ACTIVITY SMMT Insider Activity Number of Insider Trades Data is …Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to 14,312,977 shares of the Company’s ...Web

Summit Therapeutics (NASDAQ: SMMT ) announced during its Third Quarter 2023 Earnings and Update Call that it has started enrolling for the second Phase III clinical trial for ivonescimab, a potential treatment for non-small cell lung cancer. The company also introduced its new Chief Operating Officer, Manmeet Soni, who has made a $5 million …WebCEO. Website. 2003. 77. Bob Duggan. https://www.summittxinc.com. Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily …Oxford, UK, and Cambridge, MA, US, 14 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today presented in vivo proof of concept ...Sarepta Ian Estepan: Tel: 617-274-4052 [email protected] W2O Group Brian Reid: Tel: 212-257-6725 [email protected] 4, 2023 · TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders. Insiders own 8.59% of the company shares, while shares held by institutions stand at 64.76% with a share float percentage of 70.85%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 282 institutions that hold shares in the company. Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, SMT ...Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it has demonstrated the potential of its DDS-04 series of new class ...

Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer and ...

Should You Buy or Sell Summit Therapeutics Stock? Get The Latest SMMT Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at ...

Follow. Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its ...Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that Erik Ostrowski will ...MENLO PARK, Calif.--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the “Expiration Date”).As a reminder, the subscription price per share …WebNasdaq. 14,305.03 +78.81 ... Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have ...Summit Therapeutics Inc. (NASDAQ:SMMT) has the sixth position on our list of the ten best penny stocks to buy in September. It is a Cambridge, Massachusetts-based clinical-stage drug discovery and ...WebSummit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK.Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter …Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Cambridge, Massachusetts, and we have additional offices in Oxford, UK ...WebSummit Therapeutics Inc (NASDAQ:SMMT)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting -1.00. At the close of trading, the stock’s price was $2.00, to imply an increase of 2.56% or $0.05 in intraday trading. The SMMT share’s 52-week high ...May 3, 2023 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call ...Summit Therapeutics Inc (NASDAQ:SMMT) trade information. Sporting 7.07% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 11/14/23 when the SMMT stock price touched $1.97 or saw a rise of 0.51%.Summit Therapeutics Inc. Common Stock (SMMT) Nasdaq Listed. DATA AS OF Nov 26, 2021. 0. Add to Watchlist. Add to Portfolio. SMMT SMMT HISTORICAL DATA. Instagram:https://instagram. simon quicktrading taxesundervalued oil stocksrenttherunway com há 10 horas ... Price Performance Review of SMMT. On Friday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock jump 4.93% to $2.13. On the same session, the ...Dec 6, 2022 · Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ... electric vehicles companiestrading view reviews Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has ...Nov 8, 2023 · The public float for SMMT is 111.75M, and currently, short sellers hold a 9.57% ratio of that floaft. The average trading volume of SMMT on November 08, 2023 was 1.02M shares. SMMT) stock’s latest price update. Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has plunge by -12.16relation to previous closing price of 2.18. forex course Summit Therapeutics Inc. Common Stock (SMMT) 0 Add to Watchlist Add to Portfolio SMMT SMMT INSIDER ACTIVITY SMMT Insider Activity Number of Insider Trades Data is …78% of the company is held by a single shareholder (Robert Duggan) Insiders have been buying lately. If you want to know who really controls Summit Therapeutics Inc. ( NASDAQ:SMMT ), then you'll ...Dec 4, 2023 · Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders. Insiders own 18.50% of the company shares, while shares held by institutions stand at 9.14% with a share float percentage of 11.21%. Investors are also buoyed by the number of investors in a company, with Avenue Therapeutics Inc having a total of 17 institutions that hold shares in the ...